Alaska Medical Assistance DUR Committee Meeting Minutes

Friday, September 16th, 2022

Meeting was held telephonically due to COVID-19. 1:00 PM

Drug Utilization Review Committee Attendees

Members Present	Non-Members Present
Erin Narus, PharmD (DOH)	Umang Patel, PharmD (Magellan)
Charles Semling, PharmD (DOH)	Ryan Ruggles, PharmD, MSHI (Magellan)
Charles Ryan, MD	Suzanne Ishii-Regan
Matthew Begay-Bruno, PharmD	
Robert Carlson, MD	
Keri McCutcheon, RPh	Members Absent
	Jonathon Harrison, PharmD

Call to order at 1:03 PM.

Charles Semling asked for all members of the public to identify themselves.

Review of minutes from April 2022

The committee reviewed the minutes. No change required.
Keri McCutcheon moved to approve the minutes.
No opposition.

Review of Agenda

Charles Semling went over the agenda for the committee members.

Overview of Medicaid Prescription and Cost Trends

Trend snapshot was reviewed with the committee. Significant increases in cost year over year. Cost is driving the increase, not more utilizers or claims. Medicaid utilizers did increase a small amount but was not the driving factor in the increase. The trend charts also showed the increasing cost over time.

Top 10 therapeutic classes were reviewed, and it was mentioned that they have remained the same and there were no large changes. Diabetic therapy has moved up the ranks and is being driven by Ozempic.

Top 25 reports were shown to the committee comparing the movement of different drugs in total prescription count. Ondansetron had moved up 17, and oxycodone/apap has moved down. Ozempic has now been made part of the top 25 from rank 74. By reimbursement Ozempic is now number 2. Opioid dependence medications have remained in the top 25. The committee questioned if our top drugs are similar to other states. The state commented that they would expect to see many of the same drugs due to cost of drugs and number of patients. Patients changing locations to receive better care was discussed.

Prospective Drug Utilization Review/Clinical Topic Areas

New Prescription Medications (Interim PA List – 6 month review)

New items proposed for the interim PA list was presented to the committee. Norliqva (amlodipine) used for the treatment of COVID-19 was pointed out to the committee. Smallpox treatment was discussed. It was discussed how each item was classed.
Robert Carlson moved to approve the additions of the drug list.
Charles Ryan seconded.
No committee opposition.

New Prior Authorizations, Quantity Limits, Edits

The committee went into a brief closed session.

Suzanne Ishii-Regan discussed her experiences with the committee. The committee expressed their gratitude that she was able to speak.

The committee exited closed session.

Evrysdi and Spinraza criteria was presented to the committee. The state mentioned that they reached out to the individual companies, and they agreed that the criteria was appropriate. Administration location was discussed.
Keri McCutcheon moved to approve.
Charles Ryan seconded.
No committee opposition.

Soliris and Ultomiris criteria was presented to the committee. The only change was that Ultomiris is now approved to be used for generalized myasthenia gravis.
Keri McCutcheon moved to approve.
Charles Ryan seconded.
No committee opposition.

Dupixent criteria was presented to the committee. Changes were made to age ranges, and eosinophilic esophagitis criteria was added. Chronic rhinosinusitis with nasal polyposis was adjusted to require 2 different trials of steroids. For moderate to severe asthma changing the eosinophil count to >=150cells/mcL. The number of milligrams was also altered. Prior therapies were pointed out for eosinophilia esophagitis. A 30-day trial was discussed and added as the last requirement for this condition.
Keri McCutcheon moved to approve.
Matthew Begay-Bruno seconded.
No committee opposition.

Mayzent criteria was presented to the committee. A new black box warning caused the adjustment of the criteria and was added to the denial criteria.
Charles Ryan moved to approve.
Keri McCutcheon seconded.
No committee opposition.

Opzelura criteria was presented to the committee. A new indication was approved. The committee inquired to the number of patients on this medication. There has been no utilization in the past year.
Robert Carlson moved to approve and recommended reviewing in the future if there seems to be any issues.
Keri McCutcheon seconded.
No committee opposition.

Oxbryta criteria was presented to the committee. The age range was altered to reflect the new approval age range.
Charles Ryan moved to approve.
Matthew Begay-Bruno seconded.
No committee opposition.

Xolair criteria was presented to the committee. A new section for nasal polyps was added to criteria.
Charles Ryan moved to approve.
Robert Carlson seconded.
No committee opposition.

Benlysta criteria was presented to the committee. Patient age range was adjusted on the criteria.
Charles Ryan moved to approve.
Robert Carlson seconded.
No committee opposition.

Myfembree criteria was presented to the committee. New indication was added. Discussion of the adjustment of denial criteria was discussed and added for having hepatic impairment or liver disease. It was noted that CHILD Pugh classes specifically indicate the denial.
Matthew Begay-Bruno moved to approve.
Keri McCutcheon seconded.
No committee opposition.

Proton pump inhibitors criteria was presented to the committee. It was recommended to retire the criteria and keep quantity limits.
Robert Carlson moved to approve the removal.
Charles Ryan seconded.
No committee opposition.

Long-acting beta2-adrenergic agonists criteria was presented to the committee. It was recommended to retire the criteria. There were only 8 claims for this product in the previous quarter.
Robert Carlson moved to approve the removal.
Charles Ryan seconded.
No committee opposition.

Opioid tables were reviewed with the committee. The report included MAT therapies, which was different than what had been previously presented. It was noted that the number of 50-200 mme patients has decreased. It was pointed out that the medication assisted therapy medications had taken over the list of the top 20 prescribed opioid medications. Top prescriber list was noted how many of them had very low mme due to the MAT therapies.

ICD10 reports for opioids has remained near 70%.

Specialized Counseling will be brought to the next meeting.

FDA Label Changes/FAERS Reports

FDA communication "FDA Approval of lymphoma medicine Ukoniq is withdrawn due to safety concerns" was shared with the committee.

FDA communication "FDA Drug Safety Communication" with the topic of Copiktra was shared with the committee.

FDA communication "FDA recommends thyroid monitoring in babies and young children who receive injections of iodine-containing contrast media for medical imaging" was shared with the committee.

FAERS Report from January – March 2022 was shared with the committee.

End of Public Meeting

Adjournment 2:50 p.m.

Next meeting date November 18th, 2022.